Prostacyclin synthetase activity in diabetic human venous tissue.
The purpose of this study was to ascertain if alterations were present in the prostacyclin synthetase (PGI2ase) activity in diabetic human venous tissue. Saphenous veins were obtained from a group of 12 patients with (HSV-D) or without (HSV-ND) diabetes who were undergoing coronary artery bypass surgery. 14C-Labeled prostaglandin endoperoxide (PGH2) was incubated for 2 minutes with venous microsomal protein. The products were separated by thin-layer chromatography and quantified by radiochromatographic scan. PGI2ase activity was determined by the formation of 6-keto-PGF1 alpha, the stable breakdown product of prostacyclin (PGI2). Results of this study indicate the following: both HSV-ND and HSV-D specimens have active PGI2ase and are capable of forming PGI2; there is no difference between PGI2ase activity in HSV-D and HSV-ND specimens; and in diabetes mellitus, any defects in PGI2 production similar to those associated with diabetes in other investigations must reside higher in the arachidonic acid cascade.
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000328:Adult; D000368:Aged; D003577:Cytochrome P-450 Enzyme System; D003920:Diabetes Mellitus / Q000201:enzymology*; D011464:Epoprostenol / Q000096:biosynthesis* / Q000378:metabolism; D005260:Female; D006801:Humans; D019746:Intramolecular Oxidoreductases; D008297:Male; D008875:Middle Aged; D011463:Prostaglandins H / Q000378:metabolism; D012501:Saphenous Vein / Q000201:enzymology; D014680:Veins / Q000201:enzymology*
D011463:Prostaglandins H; D015121:6-Ketoprostaglandin F1 alpha; D003577:Cytochrome P-450 Enzyme System; D011464:Epoprostenol; D019746:Intramolecular Oxidoreductases; C022461:prostacyclin synthetase